scholarly journals Brain Aging and Gut–Brain Axis

Nutrients ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 424 ◽  
Author(s):  
M. Mohajeri
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Brain Development ◽  
Neurodegenerative Disorders ◽  
Gut Microbiome ◽  
Brain Aging ◽  
And Function

In the last decade, the microbiome in general and the gut microbiome in particular have been associated not only to brain development and function, but also to the pathophysiology of brain aging and to neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), depression, or multiple sclerosis (MS) [...]

scholarly journals Ongoing Research on the Role of Gintonin in the Management of Neurodegenerative Disorders

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1464 ◽  
Author(s):  
Muhammad Ikram ◽  
Rahat Ullah ◽  
Amjad Khan ◽  
Myeong Ok Kim
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorders ◽  
Disease Models ◽  
Ongoing Research ◽  
Lpa Receptor ◽  
Surface Receptors ◽  
Cellular Effects

Neurodegenerative disorders, namely Parkinson’s disease (PD), Huntington’s disease (HD), Alzheimer’s disease (AD), and multiple sclerosis (MS), are increasingly major health concerns due to the increasingly aged population worldwide. These conditions often share the same underlying pathological mechanisms, including elevated oxidative stress, neuroinflammation, and the aggregation of proteins. Several studies have highlighted the potential to diminish the clinical outcomes of these disorders via the administration of herbal compounds, among which gintonin, a derivative of ginseng, has shown promising results. Gintonin is a noncarbohydrate/saponin that has been characterized as a lysophosphatidic acid receptor (LPA Receptor) ligand. Gintonin may cause a significant elevation in calcium levels [Ca2+]i intracellularly, which promotes calcium-mediated cellular effects via the modulation of ion channels and cell surface receptors, regulating the inflammatory effects. Years of research have suggested that gintonin has antioxidant and anti-inflammatory effects against different models of neurodegeneration, and these effects may be employed to tackle the neurological changes. Therefore, we collected the main scientific findings and comprehensively presented them, covering preparation, absorption, and receptor-mediated functions, including effects against Alzheimer’s disease models, Parkinson’s disease models, anxiety and depression-like models, and other neurological disorders, aiming to provide some insights for the possible usage of gintonin in the management of neurodegenerative conditions.

Neurodegenerative Disorders and Aging Alzheimer's Disease and Parkinson's Disease ? Common Ground

1988 ◽  
Vol 515 (1 Central Deter) ◽  
pp. 411-420 ◽  
Author(s):  
R. W. HAMILL ◽  
E. CAINE ◽  
T. ESKIN ◽  
L. LAPHAM ◽  
I. SHOULSON ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorders ◽  
Common Ground

Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease

1994 ◽  
Vol 8 (6) ◽  
pp. 519-525 ◽  
Author(s):  
David C. Rubinsztein ◽  
Charlotte S. Hanlon ◽  
Richard M. Irving ◽  
Sandy Goodburn ◽  
D.Gareth R. Evans ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Late Onset ◽  
Apo E

scholarly journals Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders

2021 ◽  
Vol 15 ◽  
Author(s):  
Yoo Jin Jung ◽  
David Tweedie ◽  
Michael T. Scerba ◽  
Dong Seok Kim ◽  
Maria Francesca Palmas ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorders ◽  
Neurological Disorders ◽  
Meta Analysis ◽  
Inflammatory Factors ◽  
Sample Type ◽  
Post Traumatic Stress

Neuroinflammation represents a common trait in the pathology and progression of the major psychiatric and neurodegenerative disorders. Neuropsychiatric disorders have emerged as a global crisis, affecting 1 in 4 people, while neurological disorders are the second leading cause of death in the elderly population worldwide (WHO, 2001; GBD 2016 Neurology Collaborators, 2019). However, there remains an immense deficit in availability of effective drug treatments for most neurological disorders. In fact, for disorders such as depression, placebos and behavioral therapies have equal effectiveness as antidepressants. For neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, drugs that can prevent, slow, or cure the disease have yet to be found. Several non-traditional avenues of drug target identification have emerged with ongoing neurological disease research to meet the need for novel and efficacious treatments. Of these novel avenues is that of neuroinflammation, which has been found to be involved in the progression and pathology of many of the leading neurological disorders. Neuroinflammation is characterized by glial inflammatory factors in certain stages of neurological disorders. Although the meta-analyses have provided evidence of genetic/proteomic upregulation of inflammatory factors in certain stages of neurological disorders. Although the mechanisms underpinning the connections between neuroinflammation and neurological disorders are unclear, and meta-analysis results have shown high sensitivity to factors such as disorder severity and sample type, there is significant evidence of neuroinflammation associations across neurological disorders. In this review, we summarize the role of neuroinflammation in psychiatric disorders such as major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, and bipolar disorder, as well as in neurodegenerative disorders, such as Parkinson’s disease and Alzheimer’s disease, and introduce current research on the potential of immunomodulatory imide drugs (IMiDs) as a new treatment strategy for these disorders.

Sign in / Sign up

Export Citation Format

Share Document